Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
Brief Summary: This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.


Options:
A: Arm Label: Atorvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Ezetimibe 10 mg + Atorvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Atorvastatin, Drug: Placebo | Arm Label: Atorvastatin 80 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Rosuvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Placebo | Arm Label: Ezetimibe 10 mg + Atorvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Atorvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg, Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg, Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 80 mg, Ezetimibe 10 mg + Atorvastatin 20 mg, Ezetimibe 10 mg + Atorvastatin 40 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg + Atorvastatin 20 mg, Ezetimibe 10 mg + Atorvastatin 40 mg | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg, Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 80 mg, Ezetimibe 10 mg + Atorvastatin 20 mg, Ezetimibe 10 mg + Atorvastatin 40 mg, Rosuvastatin 40 mg
B: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Biological: Evolocumab, Drug: Standard of Care | Arm Label: Evolocumab + Standard of Care; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Drug: Standard of Care | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab + Standard of Care, Standard of Care | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Evolocumab + Standard of Care, Standard of Care
C: Arm Label: Alirocumab 75 /up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for ezetimibe), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Ezetimibe, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for ezetimibe); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W, Ezetimibe 10 mg
D: Arm Label: Bococizumab (PF-04950615;RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615;RN316) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615;RN316); Assigned to Arm(s): Bococizumab (PF-04950615;RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D